BIOLASE MAINTAINS POSITIVE MOMENTUM THROUGH YEAR END WITH SOLID FOURTH QUARTER REVENUE GROWTH; SIGNIFICANT MARKET OPPORTUNITY AND INDUSTRY-LEADING PRODUCT SUPPORT EXPECTATION FOR ROBUST REVENUE GROWTH IN 2023
FOOTHILL RANCH, Calif., Jan. 18, 2023 /PRNewswire/ -- BIOLASE , Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that based on currently available information, preliminary 2022 fourth quarter revenue is expected to be between $14.0 million and $14.4 million, well above 2021 fourth quarter revenue of $12.4 million.
- FOOTHILL RANCH, Calif., Jan. 18, 2023 /PRNewswire/ -- BIOLASE , Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that based on currently available information, preliminary 2022 fourth quarter revenue is expected to be between $14.0 million and $14.4 million, well above 2021 fourth quarter revenue of $12.4 million.
- The Company will report fourth quarter and full-year 2022 results in March 2023.
- As demonstrated by its continued positive results, the Company believes it is well positioned with its industry-leading dental lasers, broad intellectual property ("IP") portfolio, and recently bolstered balance sheet to capitalize on the significant market opportunity for dental laser adoption.
- Below are preliminary fourth quarter and full-year revenue results, a recap of the Company's 2022 key accomplishments, and anticipated operational and product milestones for 2023.